Monthly Archive: April 2013

Whats New

Informational Links & Pages on the left.
Search, Subscribe, General Info, Take A Poll on the right.
Articles & Posts Appear Below The Welcome


Up-to-the-Second Site Activity:

Latest MyQuinStory Facebook Posts:

My Quin Story shared a link. ... See MoreSee Less

View on Facebook

Fluoroquinolone Facts - Oxidative Stress ... See MoreSee Less

View on Facebook

... See MoreSee Less

View on Facebook

Melinta Therapeutics continues its aggressive promotion of the new fluoroquinolone delafloxacin, marketed under the brand name Baxdela.

Melinta is touting Baxela as being robust and safe with no cases of C. difficile diarrhea or Baxdela-related cases of tendinitis or tendon rupture, peripheral neuropathy or myopathy found in the phase three trials, undoubtedly company sponsored.

With the rise of superbugs and the current worldwide formulary of available antibiotics limited, the field of anti-infectives is ripe and willing to accept all newcomers, it is unfortunate that one of those newcomers has to be a fluoroquinolone.

As Baxdela proceeds through phase 3 trials with glowing reviews it appears that, unfortunately, we will have to prepare for those unfortunate souls in the future who will fall prey to FQAD. Since their inception, over half of the officially released FQ's have been taken off of the market due to adverse events, and all the remaining have the propensity to cause horrific adverse events. It is my opinion, since Baxdela is undoubtedly based off of the quinoline pharmacophore, it will have the same propensity for adverse events.

In an Ironic twist, they still put the safety caveat on Baxdela: "IMPORTANT SAFETY INFORMATION: WARNING: SERIOUS ADVERSE REACTIONS INCLUDING TENDINITIS, TENDON RUPTURE, PERIPHERAL NEUROPATHY, CENTRAL NERVOUS SYSTEM EFFECTS, AND EXACERBATION OF MYASTHENIA GRAVIS Discontinue Baxdela immediately and avoid the use of fluoroquinolones, including Baxdela, in patients who experience any of these serious adverse reactions." What they don't tell anyone is, once a patient experiences one of these adverse events, stopping the medication will not undue the damage already done.

Baxdella was one of six new quinolones that are in development that I wrote about in July of this year.
... See MoreSee Less

View on Facebook

To my most ardent critic in the medical profession, you know who you are, who calls my claims of the fluoroquinolones as being chemotherapy (anti-cancer or anti-tumor), "sensationalism" and "pure speculation", here are some links for your edification:

I could post many more, but these should be enough to defend my position. I know that it is cliché, but knowledge is power. Here's a thought, instead of criticizing, why not use critical thinking instead and look at the merits of the argument despite your presuppositions.

When researchers from within your own field have already developed an anti-cancer quinolone, based off of Levaquin scaffold as I recall, and that product is currently on the market, your argument becomes untenable and reduced to baseless criticism.
... See MoreSee Less

View on Facebook